US Bancorp DE Sells 2,183 Shares of McKesson Corporation $MCK

US Bancorp DE reduced its holdings in shares of McKesson Corporation (NYSE:MCK) by 2.6% in the third quarter, Holdings Channel reports. The institutional investor owned 81,577 shares of the company’s stock after selling 2,183 shares during the period. US Bancorp DE’s holdings in McKesson were worth $63,023,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in MCK. J.W. Cole Advisors Inc. raised its holdings in shares of McKesson by 35.3% in the third quarter. J.W. Cole Advisors Inc. now owns 5,089 shares of the company’s stock valued at $3,931,000 after purchasing an additional 1,329 shares during the last quarter. Private Wealth Partners LLC increased its stake in McKesson by 5.6% in the 3rd quarter. Private Wealth Partners LLC now owns 31,841 shares of the company’s stock valued at $24,598,000 after buying an additional 1,682 shares during the last quarter. AlphaQuest LLC lifted its position in shares of McKesson by 91.2% during the 3rd quarter. AlphaQuest LLC now owns 1,767 shares of the company’s stock worth $1,365,000 after buying an additional 843 shares in the last quarter. CW Advisors LLC boosted its stake in shares of McKesson by 282.5% in the 2nd quarter. CW Advisors LLC now owns 11,008 shares of the company’s stock worth $8,067,000 after buying an additional 8,130 shares during the last quarter. Finally, Envestnet Asset Management Inc. boosted its stake in shares of McKesson by 12.4% in the 3rd quarter. Envestnet Asset Management Inc. now owns 330,647 shares of the company’s stock worth $255,438,000 after buying an additional 36,451 shares during the last quarter. 85.07% of the stock is owned by institutional investors.

Insider Buying and Selling

In related news, EVP Leann B. Smith sold 190 shares of the business’s stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $945.00, for a total transaction of $179,550.00. Following the completion of the transaction, the executive vice president owned 2,989 shares of the company’s stock, valued at approximately $2,824,605. The trade was a 5.98% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Maria Martinez sold 349 shares of the stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $939.87, for a total transaction of $328,014.63. Following the completion of the sale, the director owned 301 shares in the company, valued at $282,900.87. This represents a 53.69% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 1,143 shares of company stock valued at $1,046,070 over the last three months. Insiders own 0.08% of the company’s stock.

Analyst Ratings Changes

A number of brokerages recently commented on MCK. Wall Street Zen lowered McKesson from a “buy” rating to a “hold” rating in a report on Saturday, November 8th. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of McKesson in a research report on Wednesday, December 10th. Robert W. Baird set a $968.00 target price on McKesson in a research note on Wednesday, January 14th. TD Cowen increased their price target on shares of McKesson from $1,000.00 to $1,012.00 and gave the company a “buy” rating in a research report on Thursday, February 5th. Finally, Mizuho raised their price objective on shares of McKesson from $880.00 to $885.00 and gave the stock a “neutral” rating in a report on Thursday, February 5th. Thirteen research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $943.50.

McKesson Stock Performance

Shares of MCK opened at $973.59 on Friday. McKesson Corporation has a fifty-two week low of $619.48 and a fifty-two week high of $977.27. The business has a 50-day moving average of $865.48 and a 200 day moving average of $803.36. The firm has a market cap of $119.26 billion, a P/E ratio of 28.00, a price-to-earnings-growth ratio of 1.55 and a beta of 0.40.

McKesson (NYSE:MCK) last issued its earnings results on Wednesday, February 4th. The company reported $9.34 earnings per share for the quarter, topping analysts’ consensus estimates of $9.19 by $0.15. McKesson had a net margin of 1.09% and a negative return on equity of 338.97%. The firm had revenue of $106.16 billion during the quarter, compared to analyst estimates of $105.98 billion. During the same quarter last year, the business earned $8.03 earnings per share. The company’s quarterly revenue was up 11.4% on a year-over-year basis. McKesson has set its FY 2026 guidance at 38.800-39.200 EPS. As a group, research analysts predict that McKesson Corporation will post 32.77 earnings per share for the current fiscal year.

McKesson Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, April 1st. Shareholders of record on Monday, March 2nd will be given a dividend of $0.82 per share. The ex-dividend date is Monday, March 2nd. This represents a $3.28 annualized dividend and a dividend yield of 0.3%. McKesson’s dividend payout ratio is currently 9.43%.

About McKesson

McKesson Corporation (NYSE: MCK) is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company’s core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.